Genmab — Januar 2019

[Helge_LarsenPI-redaktør]

Debatten om emnet slutter her.

[peter12]

AQR har reduceret til 1,99% igen i går

[Plimsoller]

@peter12. Tak. Hvis jeg ellers læser det rigtigt, så var der 4,4% den 28/12-2018.

[bibob]

Plimsoller. Ja, men det var alle shorts. AQR havde 2 %

[Plimsoller]

Jeps.

[E_L]

the completion date for the MAIA trial is extended for another 1 1/2 years; can we conclude anything from that? that PFS keeps improving? or is that too simple… https://clinicaltrials.gov/ct2/history/NCT02252172?A=46&B=47&C=merged

[Bulder]

or maybe to get a more reliable OS?

[E_L]

yes, that makes more sense

[peter12]

Mere dara hype fra Dr Raje Massacusetts General Hospital ca 10:30 https://youtu.be/p_Xd9JwEPEw

[gentogen]

It corresponds to what they also that "The maximum duration of study will be 7 years after last participant is randomized".

[bibob]

https://www.fiercebiotech.com/biotech/m-a-ipos-and-vc-raises-biotech-and-med-tech-execs-look-to-their-crystal-balls-for-2019?mkt_tok=eyJpIjoiTWpkbE1UZGlNbVV5T1RkaSIsInQiOiJYam1Xd2Z6UmhKYXF1SG9GeDJCR3NxWDBINkZNUUNZMFVmUHBhWlZoM0lld2FPY1lnOGdscGZwbGhsODhBUVI4Y1BmY1ZDNHZPSG41TytnZWhPZGlraUpUYzQ5XC9rdWs1Vys4Y0N5VjFLR1VPc1wvWk42cXpaNWVhbFpGNmJoK2dCIn0%3D&mrkid=41140432&utm_medium=nl&utm_source=internal

[E_L]

Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma
https://www.onclive.com/web-exclusives/daratumumabvrd-regimen-has-practicechanging-potential-in-myeloma

[Helge_LarsenPI-redaktør]

http://www.proinvestor.com/debat/76614

[JKY_VH]

og god morgen

[polle1]

God morgen

[JKY_VH]

Novod skærer kursmålet ned til 1185 fra 1233 pga højere forventet R&D omkostninger, men fortsat hold.

[JKY_VH]

Til gengæld omtaler han ikke retsagen med et ord heller ikke under Main risks.

[JKY_VH]

korrekt Pensionisten, men uanset hvad, er der tale om en reduktion på ca. 4 %.

[JKY_VH]

enig, lad os håbe at vi er kommet salgsmæssigt godt gennem Q4:-)

[bibob]

God morgen.